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        Notch receptors play an important role in cell 
growth and diff  erentiation. When binding to 
their ligands, these transmembrane receptors un-
dergo a series of proteolytic cleavages that result 
in the generation of intracellular Notch (ICN), 
which regulates transcription in a transcriptional 
complex with several other proteins after nu-
clear translocation (  1  ). Mutations that result in 
overexpression of ICN1 can be found in more 
than half of human T cell acute lymphoblastic 
lymphoma (T-ALL) samples (  2  –  4  ). These fi  nd-
ings have sparked renewed interest in ICN1-
initiated lymphomagenesis. Recent results have 
indicated that c-Myc is a target of ICN1 and 
contributes in a major way to the growth of 
Notch-dependent T-ALL cell lines (  5, 6  ). 
However, overexpression of c-Myc by itself is 
insuffi   cient to cause T-ALL, and additional events 
are required to initiate clonal growth of tumor 
cells (  7, 8  ). Girard et al. observed that frequent 
proviral insertions into the Notch1 locus en-
hanced T-ALL in c-Myc transgenic mice, sug-
gesting a collaboration of c-Myc and Notch1 
in oncogenesis that may result from the obser-
vation that ICN1 and c-Myc target overlap-
ping genes (  5  ), or that ICN1 targets distinct 
genes that facilitate c-Myc  –  dependent onco-
genesis. One of the genes that is aff  ected by 
Notch1 is the tumor suppressor E2A, which 
has an important role in the diff  erentiation of 
T and B lymphocytes (  9  ). 
  Crucial events that eventually lead to ma-
lignant transformation are diffi   cult to study ret-
rospectively in cell lines with unknown etiology 
that may have accumulated additional muta-
tions permitting growth in vitro. Therefore, we 
have systematically studied the consequences of 
overexpression of intracellular Notch 1 intro-
duced into BM cells by retroviral vectors (  10  ). 
The results identify a series of cellular and mo-
lecular changes that accompany the generation 
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  Mutations resulting in overexpression of intracellular Notch1 (ICN1) are frequently ob-
served in human T cell acute lymphoblastic leukemia (T-ALL). We have determined the 
consequences of ICN1 overexpression from retroviral vectors introduced into bone marrow 
cells. Early consequences are the generation of polyclonal nontumorigenic CD4  +  8  +   T cell 
receptor (TCR)-          +   cells that do not qualify as tumor precursors despite the observation 
that they overexpress Notch 1 and c-Myc and degrade the tumor suppressor E2A by post-
translational modifi  cation. The fi  rst tumorigenic cells are detected among more immature 
CD4       8  +  TCR-                cells that give rise to monoclonal tumors with a single, unique TCR-     
chain and diverse TCR-     chains, pinpointing malignant transformation to a stage after pre-
TCR signaling and before completion of TCR-     rearrangement. In T-ALL, E2A defi  ciency is 
accompanied by further transcriptional up-regulation of c-Myc and concomitant dysregu-
lation of the c-Myc-p53 axis at the transcriptional level. Even though the tumors consist 
of phenotypically heterogeneous cells, no evidence for tumor stem cells was found. As 
judged by array-based comparative genomic hybridization (array CGH) and spectral karyo-
type (SKY) analysis, none of the tumors arise because of genomic instability. 
© 2008 Li et al.  This article is distributed under the terms of an Attribution–Non-
commercial–Share Alike–No Mirror Sites license for the fi  rst six months after the 
publication date (see http://www.jem.org/misc/terms.shtml). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
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by the notion that the resulting monoclonal T-ALL carry a sin-
gle TCR-     rearrangement (  Fig. 2 a  ) but express diverse TCR-     
chains, as indicated by the partial staining of          TCRs with 
antibodies specifi  c for one particular V     subgroup only (  Fig. 
2 b  ).   Thus, malignant transformation of ICN1-overexpress-
ing cells is an event that occurs after pre-TCR signaling, but 
before the acquisition of the CD4  +  8  +   TCR-          +   phenotype. 
In fact, some of the monoclonal tumor cells do not express an 
         TCR on the cell surface, which is likely caused by the 
observation that they did not succeed in generating produc-
tive TCR-     rearrangements. The malignant potential of the 
phenotypically distinct tumor cells is refl  ected in their DNA 
labeling kinetics that are faster than those of their normal 
counterparts with the same surface phenotype. This is true 
for the   “  early  ”   ICN1-overexpressing CD4       8  +   TCR-                
cells that cause malignancy after transfer into nu/nu mice and 
also for the CD4  +  8  +   and CD4       8  +   TCR-          +   tumor cells that 
each can cause malignant tumors on their own after transfer 
into nu/nu recipients even when injected in low cell num-
bers. The analysis showing that each phenotypically distinct 
subset causes tumors with identical kinetics when injected in 
diff  erent doses refutes the possible notion that the subset with 
the most immature phenotype, i.e., the CD4       8  +   TCR-                
subset features tumor stem cells, whereas the more mature 
subsets feature tumor mass but not necessarily highly tumori-
genic cells (  Fig. 1 d   and   Fig. 3  ).   On the basis of these data, it 
appears useful to distinguish between normal CD4  +  8  +   TCR-
          +   thymocytes, abnormal nonmalignant and nontumori-
genic ICN1-overexpressing CD4  +  8  +   TCR-          +   cells, and 
tumorigenic CD4       8  +   TCR-               , as well as CD4  +  8  +   TCR-
          +   and CD4       8  +   TCR-          +   tumor cells when further ana-
lyzing tumor development at the subcellular level. We assume 
that the nontumorigenic but abnormal CD4  +  8  +   cells are de-
rived from ICN1-overexpressing CD4       8  +   TCR-                pre-
cursors that have failed to undergo malignant transformation 
because of a genetic status not suited to cooperate with 
Notch1 overexpression to generate malignant transformation 
(see Discussion). Because this sequence of events after ICN1 
overexpression has not been elaborated previously, it seems 
important to remember the contribution of the diff  erent sub-
sets to malignancy when further analyzing gene expression. 
  Posttranslational elimination of E2A-encoded tumor 
suppressor proteins 
  Because ICN1 overexpression results in ablation of B cell de-
velopment (  Fig. 1 a  ), we investigated its impact on the basic 
helix-loop-helix proteins encoded by the E2A gene. These 
proteins bind as homo- or heterodimers with other basic he-
lix-loop-helix proteins as transcription factors to ubiquitous 
E-box motifs and have an essential function in B cell devel-
opment (  15  ). In fact, E2A-encoded proteins have an impor-
tant role in T cell development as well ( 14  ), and E2A-defi  cient 
mice regularly develop T-ALL (  16  ). When analyzing binding 
of E2A protein to E-box motifs by EMSA, it became clear 
that nuclear extracts of both ICN1-overexpressing polyclonal, 
nontumorigenic, and tumor cells exhibited strongly reduced 
of tumor cells (T-ALL) with extensively dysregulated gene ex-
pression in spite of a normal karyotype and genomic stability. 
    RESULTS   
  Abnormal lymphoid development from ICN1-overexpressing 
hematopoietic precursors 
  ICN1 overexpression in murine hematopoietic precursor 
cells from a retroviral IRES vector containing ICN1 and EGFP 
results in a shutdown of B cell development and ectopic T cell 
development (  Fig. 1  ) (  10  ).   Early after BM transfer (BMT) 
of retrovirally transduced cells into sublethally irradiated re-
cipients, most EGFP  +   cells resemble CD4  +  8  +   thymocytes, with 
the exception that they can be found in lymphoid organs 
outside of the thymus (  Fig. 1 a  ). Such cells become appar-
ent 2 wk after BMT and do not cause tumors when trans-
planted into nu/nu recipient mice (Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20081561/DC1). 
Consistent with their nonmalignant and nontumorigenic 
phenotype, these ICN1-overexpressing cells are polyclonal 
in regard to TCR-     rearrangement that is completed before 
the CD4  +  8  +   stage of T cell development (  11, 12  ). As deter-
mined by BrdU labeling, the nontumorigenic but abnormal 
cells have a rapid turnover, much like CD4  +  8  +   thymocytes, 
which contain     15% of dividing cells that go through one or 
two divisions before becoming small cells that subsequently 
die by apoptosis (  13  ). Accordingly, normal CD4  +  8  +   thymo-
cytes and the abnormal ICN1-overexpressing CD4  +  8  +   lym-
phoid cells incorporate BrdU quickly. After pulse labeling, 
the label of normal CD4  +  8  +   thymocytes and the abnormal 
ICN1-overexpressing CD4  +  8  +   cells is also quickly lost, in-
dicating that both cell types do not have a long intermitotic 
lifespan (  Fig. 1 b  ). However, CFSE labeling of these cell 
types followed by injection into nu/nu mice (in this case, the 
CFSE-labeled ICN1-overexpressing cells express a retroviral 
vector containing DsRed) revealed a clear diff  erence in that 
control CD4  +  8  +   thymocytes did not divide measurably and 
disappeared 2 d after transplantation, whereas some of the 
abnormal, nontumorigenic cells went through three cell divi-
sions before their disappearance by day six. Thus, abnormal 
ICN1-overexpressing CD4  +  8  +   cells early after BMT transfer 
can be distinguished from normal CD4  +  8  +   thymocytes by 
their greater, but still limited, proliferation/survival potential 
(  Fig. 1 c  ). Thus, these early appearing polyclonal cells repre-
sent neither tumor cells nor their precursors because they do 
not generate tumors upon transfer into nude mice. 
  At 2 wk, a minor subset of CD4       8  +   EGFP  +   cells could be 
observed in peripheral lymphoid tissue, which, unlike the 
abnormal CD4  +  8  +   cells, did not express an          TCR, and 
thus corresponded in surface phenotype to CD4       8  +   imma-
ture thymocytes that represent precursors of CD4  +  8  +   DP 
cells (  Fig. 1, d and e  ). When these cells were transplanted into 
nu/nu mice, they generated tumors comprised of CD4  +  8  +   
and CD4       8  +   cells with          TCRs on the cell surface. These 
data suggested that cells with malignant potential are gener-
ated after pre-TCR signaling  –  dependent TCR-     selection 
(  14  ) and before TCR-     rearrangement. This was supported JEM VOL. 205, November 24, 2008 
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  Figure 1.       Phenotypic analysis of GFP  +   cells in various tissues after transplantation of ICN1-overexpressing BM cells.   (a) Single-cell sus-
pensions were prepared from blood and BM at 2 wk and from blood, lung, and liver at 8 wk after reconstitution with retrovirally transduced BM. GFP  +  
and GFP        cells were stained with CD4 and CD8 antibodies. Infi  ltration by GFP  + CD4 + 8 +   and  GFP + CD4     8 +   malignant cells was analyzed in nonlymphoid 
organs such as lung and liver. Numbers indicate the percentage of cells within each quadrant. Data are representative of three independent experi-
ments. (b) BrdU  –  labeling kinetics: continuous (top) and pulse (bottom) BrdU labeling of lymphocytes subsets. BrdU was administered to control mice 
and mice at 2 or 8 wk after BM transplantation with ICN1-overexpressing cells. The percentage of BrdU-labeled cells was analyzed by fl  ow cytometry 
as previously described (  13  ). (c) CFSE labeling: normal CD4  + 8 +   thymocytes and ICN1-overexpressing CD4  + 8 +   splenocytes were labeled with CFSE and 
injected into nu/nu mice. Dilution of CFSE label was analyzed by FACS analysis. (d) BrdU  –  labeling kinetics: continuous (top) and pulse (bottom) BrdU 
labeling of ICN1-overexpressing TCR-            CD4     8 +   splenocytes versus control normal CD4      8 +   thymocytes. (e) TCR-     expression by various lympho-
cyte subsets in ICN1-transplanted mice at 2 wk after BMT, as well as control mice. TCR-     staining was performed with the pan  –  TCR-     antibody  H57.   2854 NOTCH-INITIATED T-ALL   | Li et al. 
teins (  Fig. 4 e  ). Similarly, reduced levels of E2A proteins were 
observed in both nontumorigenic and tumor cells. Thus, as 
observed in ICN1-overexpressing fi  broblasts (  19  ), the E2A-
encoded tumor suppressors were eliminated in ICN1-over-
expressing lymphoid cells by posttranslational modifi  cations. 
The ICN1-dependent reduction of E2A-encoded tumor sup-
pressors by itself was insuffi   cient to cause tumors within the 
fi  rst few months of observation. 
  To evaluate the role of E2A-encoded E47 protein as a po-
tential tumor suppressor in T-ALL, nondegradable mutant E47 
(  19  ) was introduced into ICN1-overexpressing tumors. Dou-
ble fl  uorescence  –  labeled tumor cells were sorted and injected 
into nu/nu recipient mice, whereas control mice received tu-
mor cells transduced with an empty EGFP vector. Cells over-
expressing E47 ( Fig. 5 ) had a clear growth disadvantage because 
they generated tumors more slowly than ICN1-overexpressing 
cells transduced with an empty vector.   Also, after injection of 
98% pure double-labeled tumor cells expressing the two retro-
viral vectors, there was some selection favoring cells no longer 
expressing mutant E47. This selection resulted in tumors in 
which half of the cells no longer expressed mutant E47, indi-
cating that in ICN1-overexpressing tumor cells, E47 can act as 
a tumor-suppressor, albeit not one that is suffi   ciently strong to 
completely prevent the outgrowth of E47  +   tumors (  Fig. 6  ).   
Thus, the posttranslational elimination of the E2A-encoded 
tumor suppressor by overexpressed ICN1 contributes to 
Notch1-induced malignant growth, which is consistent with 
the observation that this tumor suppressor has a role in pre-
venting proliferation and facilitating diff  erentiation in normal 
T cell development. On the other hand, it appears that E2A 
reduction may not be essential for tumor formation after ICNI 
overexpression because E47-overexpressing tumors could still 
be detected, albeit at a later stage. 
  Tumor-specifi  c gene expression 
  When analyzing the expression of a few specifi  c candidate 
genes such as c-Myc, NF-    B, cyclin D1, and cyclin D3 by 
activity (  Fig.4 a  ).   According to the literature, the results could 
have been caused by distinct mechanisms; the reduced activ-
ity of E2A in EMSA could have been caused by either up-
regulation of the pre-TCR by overexpressed ICN1 or by 
increased pre-TCR signaling resulting in increased Id1 or Id3 
levels that prevent binding of E2A-encoded proteins to E-
box motifs (  17, 18  ). Alternatively, overexpressed ICN1 could 
have resulted in E2A protein phosphorylation and degrada-
tion (  19  ). Apparently, the second mechanism was responsible 
because there were reduced levels of E2A protein as deter-
mined by Western blotting (  Fig. 4 b  ), but not reduced RNA 
levels as analyzed by quantitative RT-PCR analysis (  Fig. 4 c  ). 
The reduced levels of E2A-encoded proteins were caused by 
ubiquitination-dependent degradation of E2A depending on 
phosphorylation by activated ERK kinase (  Fig. 4 d  ). In fact, 
inhibition of ERK phosphorylation (  19  ) by the specifi  c MEK1 
inhibitor PD98059 restored the levels of E2A-encoded pro-
  Figure 2.       TCR expression by malignant and nonmalignant cells  . 
(a) TCR-     rearrangement in various cell types. Analysis of TCR-     rear-
rangement by Southern blot analysis in GFP  + CD4 + 8 + (GFP + /DP)  and 
GFP  + CD4     8 + (GFP + /CD8 +  ) thymocytes derived from retroviral GFP-empty 
vector  –  transplanted mice, as well as GFP  + CD4 + 8 + (GFP + /DP)  and 
GFP  + CD4     8 + (GFP + /CD8 +  ) splenocytes derived from retroviral GFP-ICN1  –
  transplanted mice at 2 and 8 wk after BMT. Molecular markers are 
shown on the left. (b) TCR-     and  TCRV-   2 expression by various lym-
phocyte subsets. (left) Staining with the pan TCR-     antibody  H57. 
(right) Staining with V    2 TCR antibody.     
  Figure 3.       Kinetic analysis of tumor development.   Various cell num-
bers of ICN1-overexpressing cells with a distinct surface phenotype (as 
indicated) were injected into nu/nu mice and the kinetics of tumor devel-
opment were monitored.     JEM VOL. 205, November 24, 2008 
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data, however, only addressed human T-ALL and murine non-
tumorigenic cells. Our results showing that murine T-ALL 
overexpress cyclin D1 are, in fact, not easily compatible with the 
notion that cyclin D3 is essential for growth of murine T-ALL. 
  To obtain further insight into diff  erential gene expres-
sion, comparative analysis of global gene expression was con-
ducted after isolation of RNA from normal CD4  +  8  +   DP 
thymocytes, nontumorigenic ICN1-overexpressing CD4  +  8  +   
cells from peripheral lymphoid tissue, and CD4  +  8  +   tumor cells 
by Aff  ymetrix chip analysis. Direct targets of Notch, such as 
Hes1, Hes5, and pT     were elevated in nontumorigenic ver-
sus normal cells and either maintained or down-regulated in 
malignant (tumor) cells, in contrast to c-Myc that was further 
up-regulated in tumor cells (Fig. S1, a and b, available at 
http://www.jem.org/cgi/content/full/jem.20081561/DC1), 
consistent with quantitative RT-PCR data and Western blot 
analysis (  Fig. 7, b and c  ). In regard to cell cycle control and 
death pathways, both nontumorigenic and tumor cells exhibited 
reduced transcription of the death-associated protein kinase 1 
(DAPK1). Reduced levels of DAPK1 are often found in tu-
mors because of the hypermethylation of its promoter (  21  ). 
Fas was down-regulated in both nontumorigenic and tumor 
cells versus normal controls. Casting a wider net, the data 
showed that tumor cells versus nontumorigenic cells were 
especially defi  cient in tumor suppressors such as the large tu-
mor suppressor 2 (LATS2), often found down-regulated in 
human lymphoma, and inhibitors of cyclin-dependent ki-
nases, such as p19 and p18 (Fig. S1 a). On the other hand, sev-
eral oncogenes, including several Ras family oncogenes, the 
Western blot, it became apparent that tumor cells exhibited 
higher levels of these proteins compared with their nontu-
morigenic but abnormal or normal counterparts (  Fig. 7, a and b  ).   
ICN1 has been described to bind specifi  cally in a transcrip-
tional complex to c-Myc (  5, 6  ), and we found c-Myc to be 
up-regulated in nontumorigenic ICN1-overexpressing cells, 
but further up-regulated in tumor cells at the level of both 
RNA and protein (  Fig. 7 c  ). It is interesting to note that in 
studies looking at cyclin D3 defi  ciency, it was concluded that 
cyclin D3 was essential for growth of T-ALL (  20  ). These 
  Figure 4.       Overexpressed ICN1 inhibits E2A activity by promoting 
protein degradation at different stages of disease development.  
(a) E2A E-box motif binding activities were analyzed by electrophoretic 
mobility shift assay (EMSA) using nuclear extracts of GFP  + CD4 + 8 +   (GFP + /
DP) cells derived from various mice. (b) E2A and phosphorylated ERK1/2 
protein expression levels were analyzed by Western blot in whole-cell 
lysates from various cells. (c) Quantitative analysis of E47 mRNA expres-
sion in various cell types. GAPDH mRNA was used as control. **, P   <   0.01, 
compared with E2A  +/      group. Data are reported as mean   ±   SEM for tripli-
cate experiments. (d) Ubiquitination assay: whole-cell lysates were immuno-
precipitated by E2A antibody. Immunoprecipitates were blotted with 
antiubiquitin antibody. (e) ICN1-induced degradation and phosphorylation 
of E2A by ERK1/2 MAP kinases. Whole-cell lysates were from various cells 
that have incubated in the absence or presence of 50   μ  M PD98059 for 90 
min; PD98059 is a specifi  c inhibitor of MEK1 and MEK2. Western blot 
analysis was performed to evaluate E2A protein expression levels.    -Actin 
is shown as loading control.     
  Figure 5.       Nondegradable mutant E47 is overexpressed in ICN1-
DsRed tumor cells.   Western blot analysis of mutant E47 protein expres-
sion in whole-cell lysates from ICN1 tumor cells transduced with the 
empty retroviral vector MSCV-IRES-GFP or retroviral construct MSCV-
IRES-GFP-MmE47.     -Actin is shown as loading sample.     2856 NOTCH-INITIATED T-ALL   | Li et al. 
morigenic versus tumor cells, indicating that p53 activity was 
increased in nontumorigenic versus tumor cells. These obser-
vations may explain the nonmalignant phenotype of the ICN1-
overexpressing nontumorigenic cells. 
  C-Myc and ICN1 overexpression are essential for tumor 
development and growth 
  The gene expression data suggest that up-regulation of c-
Myc may play an essential role in tumorigenesis, as has been 
suggested by analysis of select T-ALL cell lines (  5  ). The es-
sential role of c-Myc for tumor growth was confi  rmed in ex-
periments where fl  oxed  c-Myc  fl  /fl     (  23  ) mice were crossed 
with CD4-cre (  24  ) mice and BM cells from c-Myc  fl  /fl     CD4-
cre  +/      mice were infected with the ICN1 and EGFP bicis-
tronic retroviral vector. As shown in   Fig. 6 d  , the deletion of 
c-Myc at the CD4  +  8  +   stage of T cell development prevented 
tumor formation, but did not prevent the generation of 
EGFP  +   extrathymic nontumorigenic cells, whereas in CD4-
cre mice, tumors developed normally. Thus, c-Myc plays an 
Fyn-proto-oncogene or general transcripts of genes enhanc-
ing proliferation (CDK4) and antagonizing cell death were 
specifi  cally up-regulated in tumor cells, as were genes en-
hancing transcription and translation and representing c-Myc 
target genes (Fig. S1 b) (  5, 22  ). These data suggest a scenario 
in which high levels of ICN1 alone result in elimination or 
down-regulation of several tumor suppressors, such as E2A-
encoded proteins and DAPK1, and in up-regulation of sev-
eral Notch targets and survival genes in nontumorigenic cells, 
but only moderately up-regulated c-Myc levels. These changes, 
however, are insuffi   cient to cause malignant transformation 
and lead only to moderately increased survival/proliferation 
of cells with a CD4  +  8  +   phenotype. The nontumorigenic cells 
do, in fact, express higher Annexin V levels than tumor cells, 
indicating their higher susceptibility to apoptosis. Also, non-
tumorigenic cells still express appreciable levels of tumor sup-
pressors that are down-regulated in malignant tumor cells 
(Fig. S1, a and b). Of special interest was the observation that 
the p53 inducible nuclear protein 1 gene was up in nontu-
  Figure 6.       Essential role of ICN1 and c-Myc, but not E47, down-regulation in tumor growth  . Tumor development and growth dependent on 
c-Myc and ICN1, respectively. The empty GFP-IRES retroviral vector (a), the GFP-IRES retroviral vector containing mutant E47 (b), or the GFP-IRES retrovi-
ral vector containing DNMAML1 (c) were introduced into tumors expressing a DsRed-ICN1 retrovirus. Double-fl  uorescent tumor cells were sorted and 10  6  
cells were injected into nu/nu recipient mice. Tumor cells were analyzed when mice had developed palpable tumors. Nude mice injected with tumors con-
taining empty retroviral vectors died of lymphoma 3 wk of after transfer. Mice injected with cells containing MmE47 or DN-MAML1 developed tumors 
7 wk after injection. Double-fl  uorescent cells did not form tumors in c. (d) Analysis of GFP  +   and  GFP       cells in blood of Rag2     /   ,    c    /     mice that were     
irradiated and reconstituted with retrovirally transduced BM cells from either fl  oxed c-Myc, CD4-cre, or CD4-cre mice. CD4-cre mice were killed at 8.5 wk 
when they exhibited large lymphoblastic tumors. In contrast, CD4-cre c-Myc  FL/FL   mice developed no tumors up to 15 wk.     JEM VOL. 205, November 24, 2008 
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tumors at a much later stage compared with ICN1-express-
ing controls (  Fig. 6 c  ). These results indicate that c-Myc and 
ICN1 are both required for the maintenance of tumors as 
previously established for cell lines (  5, 25  ). 
  The c-Myc  —  p53 pathway in malignant transformation 
  The tumor suppressor p53 can counteract the oncogenic ef-
fect of elevated c-Myc by inducing cell death. This can occur 
through c-Myc  –  dependent increased production of p19  Arf   
that sequesters the p53-degrading enzyme Mdm2 in the nu-
cleolus, preventing it from reaching p53, which is thereby 
stabilized and induces apoptosis in c-Myc  –  overexpressing 
cells (  26  ). Thus, this scenario depicts the regulation of the c-
myc-p53 axis mostly by posttranscriptional mechanism. Sev-
eral mechanisms can interfere with this protective pathway, 
in particular mutations in either c-Myc (  27  ) or p53 (  28  ), or 
the activation of the c-Myc  –  dependent transcriptional repres-
sor Bmi-1 that can down-regulate p19  Arf   (  29  ). To investigate 
whether the c-Myc-p53 axis (  28  ) is intact in ICN1-depen-
dent tumor cells with elevated levels of c-Myc, we deter-
mined c-Myc and p53 levels by Western blotting. As shown 
in   Fig. 7 d  , in spite of the highly elevated levels of the c-Myc 
protein in tumor cells, the level of the p53 protein was down 
compared with nontumorigenic ICN1-overexpressing cells, 
indicating that the c-Myc  –  dependent pathway of p53 stabili-
zation was not operative in tumor cells. Furthermore, p19  Arf   
protein was down-regulated and Mdm2 protein was up-reg-
ulated in tumor cells compared with nontumorigenic ICN1-
overexpressing cells. Curiously, all changes in protein expression 
were mirrored by changes at the level of RNA, indicating the 
existence of regulatory mechanisms in addition to posttran-
scriptional modifi  cations. Also, the transcriptional repressor 
Bmi-1 was up-regulated in tumor cells at the level of RNA, 
providing an explanation for the low-level expression of p19  Arf   
at the level of RNA. 
  Normal karyotype and genomic stability of tumors 
  Recent analysis of human T-ALL lines has indicated consid-
erable genomic instability, whereas genomic instability of mu-
rine T-ALL was artifi  cially introduced ( 30  ). Also, overexpression 
of c-Myc was reported to result in genomic instability (  31  ). 
When several independent primary T-ALL samples from ICN1-
overexpressing mice samples were subjected to SKY analysis, 
it became clear that the independent T-ALL samples exhib-
ited a normal karyotype (  Fig. 8  ) as has also been observed in 
subsets of primary human T-ALL samples (  32, 33  ).   Further-
more, high-resolution oligo array  –  based comparative genomic 
hybridization of four independent primary T-ALL samples 
revealed expected deletions at the TCR-    , TCR-    , and 
TCR-     loci, as well as the lgH locus; these deletions are also 
found among the majority of normal CD4  +  8  +   thymocytes. 
Importantly, however, there were no deletions or amplifi  ca-
tions that occurred only in tumor cells, but not in normal 
cells or nontumorigenic cells, excluding genomic instability 
as the cause of malignant transformation in this mouse model. 
These results therefore show that dysregulated gene expression 
essential role in early tumor growth because it is deleted in 
CD4-expressing tumor cells, but not their CD4       8  +   TCR-
                precursors. This result is in line with reports on T-ALL 
cell lines (  23  ). 
  The essential role of ICN1 for tumor growth in vivo was 
shown by introducing dominant-negative mastermind-like 1 
(DNMAML1) (  25  ) through retroviral transduction into pri-
mary ICN1-overexpressing tumor cells using an approach 
similar to that used to test the eff  ect of mutant E47 on tumor 
development (  Fig. 6  ), i.e., the retroviral vector containing 
ICN1 and DsRed was used to generate tumors and the ret-
roviral vector containing DNMAML1 and EGFP was intro-
duced into tumor cells before transplantation into nude mice. 
Even though 99% pure double-fl  uorescent tumor cells were 
sorted and injected into nu/nu recipients, double-fl  uorescent 
cells did not form tumors, whereas DsRed, ICN1-expressing 
cells survived selectively in the injected hosts and generated 
  Figure 7.       Specifi  c gene expression  . (a) NF-    B DNA binding activity 
was analyzed by electrophoretic mobility shift assay (EMSA) using nuclear 
extracts of GFP  + /CD4 + 8 +   DP cells derived from various mice. (b) c-Myc, 
cyclin D1, and cyclin D3 protein levels in various cells were analyzed by 
Western blot in whole-cell lysates.     -Actin is shown as loading control. 
(c) Total RNA isolated from various cells was analyzed by quantitative 
real-time PCR using specifi  c primers for c-Myc. GAPDH mRNA was used 
as control. *, P   <   0.05; **, P   <   0.01. Data are shown as mean   ±   SEM for 
triplicate experiments. (d) The c-Myc-p53 axis: Western blot analysis in 
whole-cell lysates from various cells was performed.     -Actin is shown as 
loading sample. (e) Quantitative analysis of p19  Arf  , Mdm2, p53, and Bmi-1 
mRNA expression in various cells. GAPDH mRNA was used as control. **, 
P   <   0.01; ***, P   <   0.001. Data are shown as mean   ±   SEM for triplicate ex-
periments. N, CTRL GFP  +  /DP thymus; NT, ICN1, GFP  +  /DP spleen 2 wk; TU, 
ICN1 GFP  +  /DP spleen 8 wk.     2858 NOTCH-INITIATED T-ALL   | Li et al. 
mice, and hence do not qualify as tumor progenitors. Molec-
ular analysis of these early appearing nontumorigenic CD4  +  8  +   
cells revealed the ICN1-dependent, degradation of E2A tu-
mor suppressor that normally binds to ubiquitous E-box mo-
tifs and in the thymus reduces proliferation while promoting 
diff  erentiation of pre-TCR  –  expressing thymocytes (  16  ).The 
ubiquitin-dependent degradation of E2A-encoded proteins 
in ICN1-overexpressing cells explains the lack of B cell de-
velopment of ICN1-overexpressing BM cells (  15  ). 
  Nontumorigenic CD4  +  8  +   cells exhibit multiple TCR-     
rearrangements consistent with their polyclonal nonmalig-
nant and nontumorigenic phenotype. Global gene expression 
analysis confi   rmed that these cells diff   er extensively from 
normal CD4  +  8  +   thymocytes; expression of several Notch tar-
get genes is increased, as is the expression of genes involved 
in proliferation/survival, whereas RNAs coding for cell cycle 
inhibitors and death-promoting proteins are reduced. These 
data fi  t well with the functional studies showing increased 
survival and proliferation of ICN1 overexpression among 
nontumorigenic CD4  +  8  +   cells. 
  The proliferative capacity, TCR-     rearrangement status, 
and gene expression profile of these abnormal but nontu-
morigenic cells are distinct from those of monoclonal, malig-
nant CD4  +  8  +   tumor cells that express a single TCR-     chain 
but diverse TCR-     chains, implying that pre-TCR signaling 
(the pre-TCR consisting of a TCR-     chain that is disulfi  de 
linked to the invariable pre-TCR-     chain) (  34  ) makes a ma-
jor contribution to malignancy, being absolutely essential for 
T-ALL generation in some (  10  ) but not all studies (  35, 36  ). 
In fact, Notch1 signaling and pre-TCR signaling do cooper-
ate in normal T cell development to induce survival and 
proliferation (  37  ), as they do cooperate in the initiation of 
in murine T-ALL initiated by ICN1 overexpression does not 
result from genomic instability. 
    DISCUSSION   
  Cellular and molecular pathways involved in tumorigenesis 
initiated by a single aberrantly expressed gene are diffi   cult to 
study retrospectively in human tumor cell lines because of 
the unknown impact of unrelated genetic changes that may 
have independently contributed to tumor formation, as well 
as further genetic changes that are required for in vitro growth 
(  30  ). For this reason, disease progression was explored in a 
murine model of T-ALL initiated exclusively by retrovirus-
mediated overexpression of ICN1 in lin        BM cells. In fact, 
mutations resulting in overexpression of ICN1 are frequently 
observed in human T-ALL samples (  2  –  4  ). However, in all 
cases, it is unknown whether such mutations initiated tumor 
development or just contributed later to the progression of 
disease. In a mouse model of ICN1-initiated T-ALL, it was 
shown by Aster et al. that retrovirally induced overexpression 
of ICN1 in lineage-negative BM cells resulted in extrathymic 
T cell development and T-ALL (  10  ). In this study, we have 
characterized various stages during tumor development with 
the aim to defi  ne cellular and molecular pathways in ICN1-
dependent tumorigenesis. 
  BMT with cells retrovirally transduced with a bicistronic 
retroviral vector containing ICN1 and a fl  uorescence marker 
resulted after 2 wk in accumulation of CD4  +  8  +   cells outside 
of the thymus. Such ICN1-overexpressing cells were not 
only abnormal in regard to their anatomical location but also 
exhibited an extended proliferation/survival potential com-
pared with their intrathymic counterparts. These cells, how-
ever, were nontumorigenic after transplantation into nude 
  Figure 8.       Genomic analysis.   (left) SKY analysis of ICN1-induced tumor cells. SKY table of stained ICN1-induced tumor chromosomes using SKY paint 
shows the spectral, classifi  ed, and banded-inverted chromosomes. (right) Array CGH. Genomic DNAs extracted from ICN1-induced malignant tumor 
GFP  + CD4 + 8 +   (Tumor XLT7), abnormal nonmalignant ICN1-overexpressing cells GFP  + CD4 + 8 +  , and control GFP  + CD4 + 8 +   thymocytes were subjected to high-
resolution oligo array  –  based comparative genomic hybridization. Tail DNA from the same mouse was used as reference for the hybridization. Malignant 
tumor GFP  + CD4 + 8 +   cells from four independent tumor mice were analyzed by Array CGH.     JEM VOL. 205, November 24, 2008 
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much reduced compared with those in the abnormal nonma-
lignant or normal CD4  +  8  +   cells, as were levels of p19  Arf   both 
at the level of RNA and protein. Down-regulation of the 
p19  Arf   protein explains the lack of compensatory p53 up-regu-
lation that could have prevented tumor outgrowth and probably 
did so in the nonmalignant CD4  +  8  +   cells. However, it does 
not explain the up-regulation of Mdm2 and down-regulation 
of p53 at the transcriptional level. The reduced expression of 
p19  Arf   is at least in part dependent on its transcriptional repres-
sor Bmi-1, which can be up-regulated by c-Myc (  29  ) and was 
specifi  cally up-regulated in T-ALL. Thus, the reduced levels 
of p19  Arf   protein in the absence of any mutation are best ex-
plained by Bmi-1 up-regulation. It is important to stress how-
ever, that the dysregulation of the c-myc-p53 axis in T-ALL 
does not only involve the usually suspected posttranscriptional 
mechanisms, but also results from the unexplained dysregula-
tion at the transcriptional level of Mdm2 as well as p53. 
  Because of the monoclonal nature of the tumors that even-
tually develop, it is likely that another thus far unknown ge-
netic event is required for malignant transformation that does 
not depend on genomic instability, as evident from the CGH 
data. The cooperating mutation(s) require further scrutiny, 
and could conceivably involve mutations caused by genetic 
instability. However, because the tumors develop relatively 
early, and we did not fi  nd mutation by sequencing of genes in 
the c-Myc-p53 axis, we consider it more likely that the coop-
erating event is caused by insertional mutagenesis of the ret-
roviral vector itself. This hypothesis will be examined by 
determining the retroviral integration sites in tumors versus 
nontumorigenic ICN1-overexpressing cells. 
    MATERIALS AND METHODS   
  Mice.     BALB/c WT and BALB/c nu/nu mice were purchased from Taconic. 
C57BL/6 and Rag-2      /          c      /      mice were purchased from The Jackson Lab-
oratory. All mice were kept in specifi  c pathogen  –  free animal facilities at the 
Dana-Farber Cancer Institute. All animal procedures were performed in com-
pliance with the guidelines of the Dana-Farber Cancer Institute Animal Re-
sources Facility, which operates under regulatory requirements of the U.S. 
Department of Agriculture and Association for Assessment and Accreditation 
of Laboratory Animal Care, and experimental protocols were approved by the 
Animal Care and Use Committee of the Dana-Farber Cancer Institute. 
  Tumor transplantation.     Nude mice were injected with various numbers 
of tumor cells (1   ×   10  4   to 2   ×   10  6  ) and tumor development was subse-
quently monitored. 
  Recombinant DNA constructs.     The intracellular domain of the murine 
Notch1 (ICN1) retroviral vector was created by cloning a PCR-amplifi  ed 
ICN1 full-length sequence into a MSCV-IRES-DsRed vector, Mutant E47 
cDNA was cloned into a retroviral vector MSCV-IRES-GFP. The MSCV-
IRES-DsRed vector and MSCV-IRES-GFP vectors were provided by D. 
Vignali (St. Jude Children’s Research Hospital, Memphis, TN). Mutant E47 
cDNA was provided by X.H. Sun (Oklahoma Medical Research Center, 
Oklahoma City, OK) and has been previously described (  19  ). The murine 
ICN1 retroviral plasmid CMMP-ICN1-IRES-EGFP and its parent vector 
CMMP-IRES-EGFP were used in most infection experiments with ICN1. 
The retroviral construct encoding a truncated N-terminal fragment of mas-
termind-like 1 fused to EGFP (DN-MAML), and the control vector MigR1 
was provided by J.C. Aster (Brigham & Women’s Hospital, Boston, MA) 
and has been previously described (  25, 39  ). 
ICN1-dependent lymphoma. Therefore, malignant transfor-
mation causing independent tumors in diff  erent mice must 
have taken place before the completion of TCR-     rearrange-
ment because of the expression of a single TCR-     chain paired 
with diverse TCR-     chains in diff  erent cells from the same tu-
mor. This fi  ts well with the fi  nding that TCR-                CD4       8  +   
cells, i.e., immature cells that have undergone pre-TCR sig-
naling are tumorigenic and exhibit a signifi  cantly higher pro-
liferation than their normal counterparts (  Fig. 1 d  ). Because 
the ICN1-overexpressing CD 4  +  8  +   cells that appear early in 
blood are not tumorigenic, the data indicate that malignant 
transformation must occur in precursors of CD4  +  8  +   cells and 
does take place within a few weeks after BMT with ICN1-
overexpressing lineage-negative cells. 
  In contrast to the nonmalignant (nontumorigenic) 
CD4  +  8  +   TCR-          +   cells, the malignant CD4  +  8  +   TCR-          +   
or CD4       8  +   TCR-         +   cells derived from the immature CD4       8  +   
TCR-                cells continued to grow, and each phenotypically 
distinct subset was able to independently cause tumors in nu/
nu recipient mice with very similar kinetics; this is incompat-
ible with the notion that the   “  early  ”   CD4       8  +   cells represent 
tumor stem cells that generate nonmalignant TCR-          +   prog-
eny that constitutes the tumor mass. The tumorigenic poten-
tial was mirrored by the up-regulation of several oncogenes, 
most prominently the c-Myc oncogene that represents an 
ICN1 target, but also others, such as Akt and the oncogenes 
of the Ras family, the latter being considered targets of c-
Myc. Furthermore, transformed cells exhibited reduced lev-
els of cyclin-dependent kinase inhibitors p18 and p19, as well 
as elevated expression of cyclin-dependent kinase 4 (another 
c-Myc target) compared with their nonmalignant CD4  +  8  +   
counterparts. Increased c-Myc RNA levels were also re-
fl  ected in increased levels of RNAs transcribed from genes 
involved in transcription and translation such as RNA poly-
merases, as well as initiation and elongation factors, which are 
likewise considered to represent targets of c-Myc. However, 
c-Myc overexpression by itself is not suffi   cient to cause mono-
clonal tumors (  7, 8  ), and needs to be accompanied by further 
genetic changes to result in outgrowth of monoclonal tumors. 
  Apart from being an ICN1 target, c-Myc expression can 
be dramatically increased by chromosomal translocation (  38  ). 
However, SKY analysis of independent tumors did not reveal 
any translocations, indicating that overexpression was depen-
dent on transcriptional regulation of c-Myc by ICN1 (  5, 6  ). 
Furthermore, analysis by high-resolution oligo array  –  based 
comparative genomic hybridization (array CGH) did not ex-
hibit any tumor-specifi  c amplifi  cations or deletions, suggesting 
that genomic instability does not contribute to the generation of 
tumors initiated by ICN1 overexpression, in spite of the ob-
servation that c-Myc overexpression can be associated with 
genomic instability. Thus, mechanisms other than genomic 
instability must account for the observation that highly ele-
vated levels of c-Myc in tumors did not result in stabilization 
of apoptosis-inducing p53. Normally this occurs via up-regu-
lation of p19  Arf  , which then sequesters Mdm2 that can then no 
longer degrade p53. In fact, p53 levels in tumor cells were 2860 NOTCH-INITIATED T-ALL   | Li et al. 
Protein concentration of each extract was measured by OD 595 nm. 5   μ  g of 
each nuclear extract was used in each EMSA. To generate probes for EMSAs, 
5     end biotin-labeled double-stranded oligonucleotides containing the bind-
ing sites for E2A and NF-    B were synthesized from Integrated DNA Tech-
nologies. The following oligonucleotides were used for EMSA: E2A E-box 
consensus sequences, CCCCAACACCTGCTGCCTGAG; NF-    B binding 
motif, AGTTGAGGGGACTTTCCCAGGC. The probes were purifi  ed with 
PAGE. EMSA was performed using LightShift chemiluminescent EMSA kit 
(Thermo Fisher Scientifi  c), following the manufacturer  ’  s instructions. 
  Immunoprecipitation and Western blot.     Cells were lysed in radioim-
munoprecipitation assay (RIPA) buff  er supplemented with Protease Inhibi-
tor Cocktail (Sigma-Aldrich). A 1,000-  μ  g aliquot of total cell lysates was 
incubated with 10   μ  g of specifi  c antibodies or control IgG for 2 h or over-
night at 4  °  C. A 40-  μ  l aliquot of 50% protein A  –  agarose slurry was added and 
incubated for another hour, followed by several washes with 0.1% NP-40 in 
PBS. The precipitates bound to the beads were analyzed by immunoblotting 
with Ubiquitin antibody (Santa Cruz Biotechnology, Inc.). 
  For Western blot analysis, cells were lysed in RIPA buff  er supplemented 
with Protease Inhibitor Cocktail (Sigma-Aldrich). Lysates (40   μ  g) were sepa-
rated on 4  –  20% SDS-PAGE and transferred onto PVDF membrane (Milli-
pore). Nonspecifi  c binding was blocked by incubation in blocking buff  er 
(5% nonfat milk in TBST), followed by incubation with the primary anti-
bodies and the appropriate horseradish peroxidase  –  conjugated secondary anti-
bodies diluted in blocking buff  er. Immunoreactive proteins were detected 
using enhanced chemiluminescence (ECL) reagents (GE Healthcare). The 
E2A, Mdm2 antibodies were purchased from BD. ERK1/2, phosph-ERK1/2 
antibodies, and MEK1/2-specifi  c inhibitor PD98059 were purchased from 
Cell Signaling Technology. Cyclin D3 antibody was obtained from Santa 
Cruz Biotechnology. Cyclin D1 antibody was purchased from NeoMarker, 
and the p19  Arf   and c-Myc antibodies were purchased from Abcam. p53 
antibody was provided by R. Depinho (Dana-Farber Cancer Institute, 
Boston, MA). 
  Quantitative RT-PCR.     cDNA was prepared by oligo-dT primer using the 
Superscript II Reverse Transcription kit (Invitrogen). Quantitative RT-PCR 
was performed using an ABI7300 machine (Applied Biosystems). c-Myc, E47, 
Bmi-1, p19  Arf  , Mdm2, and p53 RNA was determined relative to GAPDH ex-
pression using the TaqMan Gene Expression Assay (Applied Biosystems). All 
quantitative RT-PCR reactions were done in triplicate in 20   μ  l volume. 
  Microarray analysis.     Sorted cells were homogenized for RNA isolation 
using the TRIZOL reagent (Invitrogen) and purifi  ed  using  QIAGEN 
RNeasy minicolumns. RNA samples were processed for hybridization on 
the Mouse Expression-Array-430.2.0 Genechips (Aff  ymetrix) by the Micro-
array Core Facility of the Dana-Farber Cancer Institute. Data were loaded 
onto the DNA-Chip Analyzer (dChip; http://www.dchip.org) program for 
normalization and quantifi  cation. Normalization was performed using the 
default settings of the dChip software, genes were selected for expression 
diff  erences higher than 1.5-fold by Student  ’  s   t   test (P   <   0.05) or for signifi  -
cant changes (P   <   0.05). The microarray data have been deposited in the 
GEO database under accession no.   GSE12948  . 
  Online supplemental material.     Fig. S1 shows global gene expression profi  l-
ing in control, abnormal nonmalignant cells, and tumor cells. Table S1 provides 
tumorigenicity assays in nu/nu homozygous mice. The online version of this   
article is available at http://www.jem.org/cgi/content/full/jem.20081561/DC1. 
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  Retrovirus production and BM transplantation.     Retroviral superna-
tants were produced by transient transfection of 293T cells with the retro-
viral construct and appropriate packaging plasmids (provided by H. Cantor, 
Dana-Farber Cancer Institute, Boston, MA). Retroviral infection and BM 
reconstitution experiments were performed as previously described (  20, 36, 
40  ). In brief, lineage-negative (CD3e, TCR-    , NK1.1, DX5, CD19, Ter-
119, Mac-1, and Gr-1) BM cells were sorted from BALB/c or CD4-Cre c-
Myc  fl  ox/fl  ox   and C57BL/6 mice and cultured in the presence of Flt3L, SCF, 
IL-6, and IL-7 (all from R  &  D Systems). On day 2 and 4 after sorting, cells 
were subjected to retroviral transduction by centrifugation at 2,300 rpm for 
1.5 h at room temperature with 8   μ  g/ml polybrene. On day 5, 1  –  2   ×   10  6   
cells were injected intravenously into irradiated (550 rad) 5  –  8-wk-old syn-
geneic BALB/c or RAG 2      /          c      /      recipients. 
  Flow cytometry and cell sorting.     Monoclonal antibodies specifi  c for 
CD4 (RM4-5, GK1.5), CD8 (53  –  6.7), TCR-     (H57-597), CD3e(145-
2C11) Gr-1 (RB6-8C5), erythroid cell marker (Ter-119), CD19 (1D3), 
CD11b (M1/70), pan-NK (DX5), and NK1.1 (PK136) were purchased 
from BD and were used as biotin, FITC, PE, peridinin chlorophyll protein 
(PerCP), PerCP-Cy5.5, PE-Cy7, allophycocyanin (APC), or APC-Cy7 con-
jugates. Single-cell suspensions were prepared from peripheral blood, BM, 
spleen, lymph node, thymus, lung, and liver of ICN1-transplanted animals 
and related controls at the indicated time points. Cells were analyzed by 
FACSCalibur cytometer (BD) equipped with CellQuest Software (BD Bio-
sciences) and FlowJo (Tree Star, Inc.) and were sorted by a FACSAria (BD) 
or a MoFlo cell sorter (Cytomation). Sorted cells were of   >  98% purity, as 
determined by postsort analysis. 
  BrdU labeling.     BrdU incorporation procedure was performed as previ-
ously described (  13  ). In brief, mice were injected intraperitoneally with 1.8   μ  g 
freshly resuspended BrdU in water every day. Sorted cells from BrdU-treated 
mice were fi  xed, permeabilized, and stained intracellularly using the BrdU 
labeling kit from BD. 
  CFSE labeling.     Sorted CD4  +  8  +   cells were incubated with 10   μ  M CFSE (In-
vitrogen) at 5   ×   10  6   cells/ml PBS, 0.1% BSA for 10 min at 37  °  C. Cells were 
washed two times with RPMI 1640 medium to eliminate the remaining CFSE 
and injected intravenously into nude mice. Cell division of CFSE-labeled cells 
was analyzed by fl  ow cytometry on day 2, 4, 6, and day 8 after injection. 
  SKY.     Metaphase chromosomes were prepared from tumor CD4  +  8  +   cells. In 
brief, cells were treated with colcemid for 2 h, and then incubated in 0.075 
M KCl for 20 min at 37  °  C. Chromosomes were subsequently fi  xed in 3:1 
methanol/acetic acid. Metaphases were dropped on slides, dried overnight, 
and stained with DAPI before microscopic examination. SKY was done us-
ing the SkyPaint DNA kit for mouse samples (Applied Spectral Imaging) ac-
cording to the manufacturer  ’  s instructions. Spectral images were captured 
using a microscope (E800; Nikon) equipped with ASI spectral cube, 60  ×   
objective, and analyzed using SKYView software from Applied Spectral 
Imaging. At last 20 metaphases were analyzed per sample. 
  Array CGH Profi  ling.     Genomic DNA from sorted cells was extracted us-
ing DNeasy Tissue kit (QIAGEN) and processed for hybridization by the 
Belfer Cancer Genomics Center, Dana-Farber Cancer Institute. The DNA 
was hybridized to 244 K Whole Mouse Genome Chip (G4122A; Agilent 
Technologies) according to the manufacturer  ’  s instructions. Tail DNA from 
the same mouse as reference. The median spatial resolution for this chip is 
8.05 Kb; probes cover all known genes. Data were assembled and analyzed 
using CGH Analytics software (Agilent Technologies). 
  Southern blot analysis.     10   μ  g of genomic DNA was digested with EcoRI 
overnight at 37  °  C, separated on a 1.0% agarose gel, transferred onto nitro-
cellulose membrane. After UV cross-linking, the blot was hybridized with a 
p  32  -labeled probe from the J    2 region of the TCR-     gene. 
  Electrophoretic Mobility Shift Assays (EMSA).     Nuclear extracts were 
prepared from cells using nuclear and cytoplasmic extraction reagents (PIERCE). JEM VOL. 205, November 24, 2008 
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